COLL
Collegium Pharmaceutical Inc
22.60$
+0.8%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -2.9% | -2.5% | -5.5% | +55.2% | +1.7% | -1.9% | -2.4% | +0.9% | +3.1% | -0.3% | +29.3% | |
| – | +0.1% | +0.3% | -5.4% | -13.0% | +8.7% | +9.4% | +4.1% | +11.8% | +12.6% | +7.8% | -18.5% | |
| – | -7.6% | -4.3% | -24.4% | -77.5% | +81.1% | +36.3% | +22.0% | +44.8% | +47.8% | +7.0% | -51.8% | |
| – | +2.0% | +2.4% | -14.6% | -55.8% | +35.7% | +21.5% | +12.3% | +37.6% | +33.0% | +3.7% | -69.3% | |
| – | -1.3% | -2.7% | +5.2% | +24.3% | +0.0% | +0.1% | -6.9% | +9.8% | -9.7% | +8.2% | +24.6% | |
| – | -5.3% | -3.3% | -10.9% | +36.5% | -6.5% | +4.7% | +2.5% | -0.3% | +7.5% | +4.5% | +165.0% | |
| – | +0.0% | +0.0% | +0.0% | +9.0% | +11.2% | -7.1% | -1.9% | -1.4% | +0.0% | +0.0% | +30.3% | |
| – | -7.6% | -8.2% | -8.9% | +168.5% | -5.9% | -6.2% | -6.6% | -7.1% | -7.7% | -8.3% | +93.2% | |
| – | -5.1% | -5.9% | -6.2% | +67.4% | +2.4% | -2.6% | -2.6% | -2.1% | +1.7% | -1.2% | +36.2% | |
| – | -1.4% | -2.5% | +3.4% | -0.5% | +10.9% | -4.5% | -4.5% | -2.5% | -2.8% | -1.1% | +35.6% | |
| – | +0.0% | +0.0% | +0.0% | -64.3% | +0.0% | +0.1% | +0.1% | +0.1% | -53.9% | +12.1% | +66.0% | |
| – | +137.9% | -30.7% | -59.9% | +30.3% | +25.2% | +353.8% | -39.0% | -29.8% | +39.4% | -35.9% | +35.3% | |
| – | -8.3% | -9.1% | -16.0% | +117.2% | -1.8% | -1.9% | -1.9% | -2.0% | +4.9% | -1.3% | +34.6% | |
| – | +9.3% | +13.7% | -2.5% | +8.2% | -2.3% | +2.4% | -1.0% | +18.3% | +9.8% | +3.6% | -0.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -0.6% | -0.8% | -2.5% | -0.5% | -0.1% | -18.1% | +19.0% | +0.9% | +0.7% | +0.9% | -19.0% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.